alnylam.com (ALNY) Quarterly EPS earnings growth

Symbol and logo of brand Alnylam Corp (ALNY)

Alnylam Pharmaceuticals (ALNY) management successfully combines scientific research with sales, confirming the effectiveness of RNA technologies. However, high R&D expenditures and trial risks create financial pressure. The company is currently scaling sales, which is gradually reducing unit costs. The quarterly EPS growth rate helps assess the impact of inflation on profitability, while the 754.70 mark serves as the current indicator on this chart.

ALNY: Alnylam Year-over-year earnings per one share growth for the last 12 months 07/04/2022 - 11/17/2026

Alnylam Pharmaceuticals (ALNY) - metric breakdowns and financial figures

- share price and expert price forecast:
Initial company analysis:Alnylam Pharmaceuticals
Flagship merchandise of Alnylam Corp

Quarterly EPS growth measures the dynamics of net income per share, revealing the business's ability to overcome cost inflation. Analyzing the history of quarterly EPS changes allows one to distinguish sustainable scaling from temporary resource savings. A positive trend confirms the effectiveness of operational capital management. For Alnylam Pharmaceuticals (ALNY), this indicator reflects the success of its own science without external acquisitions. Profit growth here directly depends on global licensing alliances.

Who Alnylam Pharmaceuticals competes with

VRTX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Insmed Inc (INSM)|UTHR (United Therapeutics Corporation) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months BMRN (BioMarin)|Year-over-year net earnings per share growth for the last 12 months BBIO (BridgeBio)|BGM: Year-over-year net earnings per share trend for the last twelve months|Year-over-year earnings per share growth for the last twelve months Cogent Biosciences, Inc. COGT|XERS (Xeris Biopharma Inc) - Year-over-year net earnings per share trend for the last twelve months|Keros Therapeutics - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months ARCT (Arcturus Therapeutics)|ETON: Quarterly EPS earnings growth|Kamada Ltd (KMDA) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Fulcrum Tx|ABEO: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Mereo BioPharma Group (MREO)|Quarterly EPS earnings growth protalix.com (PLX)|Quarterly EPS earnings growth PLRX (Pliant Therapeutics Inc)|Quarterly EPS earnings growth Applied Therapeutics APLT|RNTX - Year-over-year earnings per share growth for the last twelve months|Net earnings per share growth for the trailing year gelteq.com (GELS)|AYTU (aytubio.com) - Year-over-year net earnings per share growth for the last 12 months|Chemomab Therapeutics Ltd - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months SRXH|Year-over-year earnings per share growth for the last twelve months PLRZ|Quarterly EPS earnings growth AEZS|Year-over-year earnings per share growth for the last twelve months CYTH (Cyclo Therapeutics, Inc)|Inozyme Pharma - Year-over-year net earnings per share growth for the last 12 months|Reneo Pharmaceuticals, Inc. (RPHM) - Earnings per share growth in annualized terms for the last twelve months|COSCIENS Bio - Quarterly EPS earnings growth